For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$656.01
Thesis
Regeneron pairs a durable, cash-generative Eylea retinal franchise with a fast-growing Dupixent business co-developed with Sanofi across atopic and inflammatory indications. The pipeline extends into oncology (Libtayo and bispecifics) and obesity-adjacent metabolic assets.
The franchise has the rare combination of high quality earnings and an active, internally discovered pipeline — biosimilar pressure on Eylea is the main overhang, with Eylea HD partly mitigating it.
Catalysts
- Eylea HD share gains slowing biosimilar erosion
- Dupixent indication expansions (COPD and beyond)
- Oncology readouts across the bispecific antibody pipeline
- Capital deployment given the strong cash position
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 6Financial resultsSEC
Regeneron filed Form 8-K item 2.02 on results of operations and financial condition.